Search Results

Atara Biotherapeutics, Inc. and Pierre Fabre Laboratories announced that data from the pivotal Phase 3 ALLELE study of tab-cel, approved in the European Union in adults and children two years of age and older with relapsed or refractory Epstein-Barr virus positive post-transplant lymphoproliferative disease following solid organ transplant or hematopoietic cell transplant, were published for the first time online in The Lancet Oncology.

Wave Life Sciences Ltd. today announced positive results from its Phase 1b/2a SELECT-HD clinical trial of WVE-003, which is being developed as a potential disease modifying therapeutic for Huntington’s disease (HD).

eyeDNA Therapeutics, a newly created subsidiary of Coave Therapeutics, a genetic medicine company focused on developing life-changing therapies, announces positive 24-month follow-up results from its Phase I/II study evaluating the safety and efficacy of HORA-PDE6b, its investigational gene therapy for retinitis pigmentosa caused by bi-allelic mutations in the PDE6b gene.